Physician profile
Brian Cravanas
NPI 1427477629
$5,747.47
in general payments reported to CMS, 2019-2025
35 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $513 · 2020: $312 · 2022: $354 · 2023: $1,948 · 2024: $1,951 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,515 · Travel and Lodging: $34.00 · Education: $19.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,514.71 |
| Travel and Lodging | $34.00 |
| Education | $19.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.72 | 2022-2025 | Botox, Ubrelvy, Qulipta |
| Acadia Pharmaceuticals INC | $773.62 | 2023-2025 | Nuplazid |
| Abbott Laboratories | $551.51 | 2019-2025 | Infinity |
| Medtronic, INC. | $354.23 | 2022-2023 | Percept PC Brainsense |
| Medtronic USA, INC. | $308.79 | 2019-2020 | |
| Pfizer INC. | $308.65 | 2023-2025 | |
| Biogen, INC. | $281.83 | 2022-2025 | Tysabri, Vumerity, Avonex |
| Neurocrine Biosciences, INC. | $239.30 | 2019-2025 | Ingrezza, Ongentys |
| Eisai INC. | $191.84 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $185.25 | 2023-2024 | Aptiom |
| Mdd US Operations, LLC | $166.21 | 2019-2023 | Apokyn |
| Novartis Pharmaceuticals Corporation | $113.77 | 2023 | |
| Ucb, INC. | $112.36 | 2024-2025 | Rystiggo, Briviact, Zilbrysq |
| Kyowa Kirin, INC. | $111.98 | 2022-2024 | Nourianz |
| Amneal Pharmaceuticals LLC | $110.36 | 2022-2024 | Rytary, Crexont |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $107.62 | 2019 | |
| Averitas Pharma INC. | $100.90 | 2023 | Qutenza |
| Livanova USA, INC. | $100.51 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Genentech USA, INC. | $67.85 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Argenx US, INC. | $67.13 | 2023-2024 | Vyvgart |
| Celgene Corporation | $63.18 | 2022-2024 | Zeposia |
| Microtransponder, INC. | $62.70 | 2024 | |
| Emd Serono, INC. | $43.32 | 2022-2023 | Mavenclad |
| Catalyst Pharmaceuticals, INC. | $42.08 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $41.76 | 2023-2024 | Austedo Xr |
| Lilly USA, LLC | $35.90 | 2023-2024 | Reyvow, Emgality |
| Corium, LLC | $25.55 | 2023 | Adlarity |
| Otsuka America Pharmaceutical, INC. | $25.20 | 2023 | Nuedexta |
| Azurity Pharmaceuticals, INC. | $21.51 | 2024 | Horizant |
| Banner Life Sciences, LLC | $20.78 | 2023 | |
| Sunovion Pharmaceuticals INC. | $16.91 | 2022 | |
| Springworks Therapeutics, INC. | $16.39 | 2025 | |
| Alnylam Pharmaceuticals INC. | $16.02 | 2024 | Amvuttra |
| Boston Scientific Corporation | $14.08 | 2023 | Vercise |
| Travere Therapeutics, INC. | $1.66 | 2022-2023 | Cholbam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Cravanas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.